23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Bonsai-induced Kounis Syndrome in a young male patient

      case-report
      , 1 , 2
      Anatolian Journal of Cardiology
      Kare Publishing

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction The use of cannabis and its synthetic derivative, bonsai, has recently increased, and it has become an important health problem (1). Kounis syndrome develops by the activation of mast cells, and it is an acute coronary syndrome (ACS) related to allergies, hypersensitivity, anaphylaxis, or anaphylactic reactions (2, 3). Bonsai-induced Kounis syndrome has not been reported in literature. The present study presents the case of a 27-year-old patient who arrived at the emergency clinic with chest pain 6 h after the use of bonsai. Case Report A 27-year-old male patient arrived at the emergency clinic with sudden-onset retrosternal pain in the left arm, vomiting, and sweating. The chest pain was characterized by pressure and burning and lasted for 6 h. The patient did not have any known atherosclerosis risk factor and reported bonsai use for the first time in his life. He expressed that he had used a great amount of bonsai 1 h before the onset of chest pain. All vital signs of the patient were stable. His electrocardiographic (ECG) investigation revealed mild bradycardia and ST segment elevations in the inferior derivations (D2, D3, and AVF) (Fig. 1). The patient was referred to the coronary intensive care unit after the diagnosis of acute inferior MI was made. Bedside echocardiography revealed inferior and septal hypokinesis. Thrombolytic therapy was planned but was then disregarded as the recently recorded ECG showed ST-segment elevations returning to the isoelectric line. Troponin I value showed a typical increase (4 h)- decrease (24-36 h) (peak value 10.722 ng/mL). Mild leukocytosis and eosinophilia (4.9%) were present. The immunoglobulin E level was high (150 mg/L). The patient was referred to a more advanced center for coronary angiography (CAG). CAG indicated that all coronary arteries were patent (Fig. 2). The fibrinogen and homocysteine levels and antithrombin activity were all within normal ranges. The patient was followed-up for three days without any complications and was then dismissed from the hospital with prescriptions for 100-mg aspirin, 90-mg diltiazem, and 40-mg atorvastatin. Figure 1 ST elevation in inferior leads on 12-derivation ECG obtained in the emergency department Figure 2 Demonstrating RCA, LMCA, LAD, and LCx on coronary angiography Discussion To our knowledge, this patient is the first bonsai-induced Kounis syndrome case in literature. Kounis syndrome, in other words allergic MI, has two types depending on the pathophysiology, or the presence of coronary artery disease. In type I, patients exhibit coronary vasospasms induced by allergic mediators such as histamine, thromboxane, and leukotrienes without the presence of atherosclerosis risk factors or coronary artery disease. In type 2, ACS develops due to coronary vasospasms, plaque erosion, or plaque rupture induced by these mediators in patients with atherosclerotic coronary artery disease. Recently, the fact that there are eosinophil and mast cells in the thrombus material excised from some patients in whom stent thrombosis developed after stent implantation with drug release makes us consider hypersensitivity reactions in these patients. This situation is accepted as the type III variant of Kounis Syndrome (4). With these findings, our case is in accordance with the type I variant of Kounis syndrome. Cardiovascular and psychological problems are frequently reported to be associated with the use of bonsai. The main pathophysiology of Kounis syndrome is the release of many allergic mediators as a result of mast cell activation induced by allergic stimulants. It has been demonstrated in experimental studies that some endogenous cannabinoids suppress inflammation by decreasing mast cell activation via receptors; however, some endogenous cannabinoids trigger mast cell activation independent from receptors (5). In our patient, coronary arteries were revealed to be completely patent, and this may cause us to consider that a coronary vasospasm was the reason that was caused via mediators released by the bonsai-induced activation of mast cells. The main cardiovascular effects are coronary vasoconstriction, increase in the synthesis of tissue factor, thrombocyte activation, dysrhythmia development induced by various mechanisms, and plaque erosion (6, 7). In a patient considered to have Kounis syndrome, in addition to appropriate ACS management, the determination of serum histamine, specific Ig E antibodies, and complement proteins and investigation of eosinophilia aid in the diagnosis (2). Leukocyte, eosinophil, and total IgE levels were increased in our patient, but other analyses could not be performed due to technical limitations. Conclusion We hoped to emphasize the consideration of the use of bonsai-type synthetic drugs in a young patient with acute MI signs but without any risk factors.

          Related collections

          Most cited references7

          • Record: found
          • Abstract: found
          • Article: not found

          Kounis syndrome: a new twist on an old disease.

          Kounis syndrome is the concurrence of acute coronary syndromes with conditions associated with mast cell activation, such as allergies or hypersensitivity and anaphylactic or anaphylactoid insults that can involve other interrelated and interacting inflammatory cells behaving as a 'ball of thread'. It is caused by inflammatory mediators such as neutral proteases including tryptase and chymase, arachidonic acid products, histamine, platelet activating factor and a variety of cytokines and chemokines released during the activation process. Platelets with FCεRI and FCεRII receptors also participate in the above cascade. Vasospastic allergic angina, allergic myocardial infarction and stent thrombosis with occluding thrombus infiltrated by eosinophils and/or mast cells constitute the three reported variants of this syndrome. Kounis syndrome is a ubiquitus disease that represents a magnificent natural paradigm and nature's own experiment, in a final trigger pathway implicated in cases of coronary artery spasm and plaque rupture. Kounis syndrome can complicate anesthesia, vaccination, medical therapy and stent implantation and it seems to be associated with coronary allograft vasculopathy and takotsubo syndrome, it can often be confused with hypersensitivity myocarditis and can be the cause of unexplained sudden death. Kounis syndrome has revealed that the same mediators released from the same inflammatory cells are present in acute coronary events of nonallergic etiology. These cells are not only present in the culprit region before plaque erosion or rupture but they release their contents just before an actual coronary event. Therefore, does Kounis syndrome represent a magnificent natural paradigm and nature's own experiment in a final trigger pathway implicated in cases of coronary artery spasm and plaque rupture showing a novel way towards our effort to prevent acute coronary syndromes? Drugs, substances targeting the stem cell factor that is essential for mast cell development, proliferation, survival, adhesion and homing as well as monoclonal antibodies and natural molecules that protect mast cell surface and stabilize mast cell membrane could emerge as novel therapeutic ways capable to prevent acute coronary and acute cerebrovascular events.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Prevalence and correlates of cannabis use in developed and developing countries.

            The aim of this article is to review recent research on the prevalence, antecedents and correlates of cannabis use in young adults in developed and developing countries. Cannabis is the most widely used illicit drug globally and its use appears to be increasing in developed and developing countries. In developed countries rebelliousness, antisocial behaviour, poor school performance, and affiliation with drug-using peers are risk factors for early and regular cannabis use. Similar antecedents are now being reported in developing countries. Dependence is an underappreciated risk of cannabis that affects one in six to seven adolescents who use cannabis in developed countries. Adolescent cannabis dependence is correlated with an increased risk of using other illicit drugs, symptoms of depression, and symptoms of psychosis. The plausibility of cannabis playing a contributory causal role has increased for symptoms of psychosis in longitudinal studies but remains contentious. In the case of other illicit drug use and mood disorders common causal explanations remain difficult to exclude. Early and regular cannabis use in adolescence predicts an increased risk of cannabis dependence which in turn predicts an increased risk of using other illicit drugs, and reporting symptoms of mood and psychotic disorders.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques.

              Recent studies suggest that mast cell-derived neutral proteases can activate matrix-degrading metalloproteinases (MMPs). We have investigated the role of the mast cell proteases tryptase and chymase in the activation of MMPs in human carotid endarterectomy specimens (atherosclerotic, n=32) and postmortem carotid arteries (control, n=17). In vitro degranulation of mast cells in atherosclerotic carotid arteries by compound 48/80 caused a significant increase in MMP activity. Addition of the nonselective tryptase inhibitor antipain, the specific trypsinlike protease inhibitor 4-amidinophenylmethanesulfonyl fluoride, and the chymase inhibitor chymostatin reduced this increase in MMP activity by 30+/-6%, 23+/-6%, and 9+/-2%, respectively. Immunocytochemistry identified significantly higher numbers of tryptase-containing cells (mast cells) and cells expressing MMP-1 and MMP-3 in the "shoulder" regions of atherosclerotic artery lesions compared with the tunica media of control arteries. Dual immunocytochemistry showed collocation of MMP-1 and MMP-3 with mast cells in the shoulder regions. Degranulation was observed in 78+/-5% (mean+/-SEM) of mast cells in this area, whereas nonactivated mast cells were observed in all other areas. In situ zymography revealed caseinolytic and gelatinolytic activity in these areas. In conclusion, in vitro mast cell degranulation, which releases mast cell proteases, in carotid arteries increases MMP activity. Furthermore, elevated MMP-1 and MMP-3 expression is collocated with increased numbers of degranulated mast cells and with greater MMP activity in the shoulder regions of atherosclerotic plaques. Activation of MMPs by mast cell-derived proteases may be an important mechanism in atherosclerotic plaque destabilization.
                Bookmark

                Author and article information

                Journal
                Anatol J Cardiol
                Anatol J Cardiol
                Anatolian Journal of Cardiology
                Kare Publishing (Turkey )
                2149-2263
                2149-2271
                November 2016
                : 15
                : 11
                : 952-953
                Affiliations
                [1]Departmant of Cardiology, Aksaray State Hospital; Aksaray- Turkey
                [1 ]Departmant of Cardiology, Şişli Etfal Education and Training Hospital; İstanbul- Turkey
                [2 ]Departmant of Cardiology, Faculty of Medicine, Erciyes University; Kayseri- Turkey
                Author notes
                Address for Correspondence: Dr. Sinan İnci Aksaray Devlet Hastanesi, Zafer Mah. Nevşehir Cad. No:117 Aksaray- Türkiye Phone: +90 382 212 35 02 E-mail: doktorsinaninci@ 123456gmail.com
                Article
                AJC-15-952
                10.5152/AnatolJCardiol.2015.6641
                5336950
                26574765
                f46fc344-0830-4345-8a50-74069021a805
                Copyright © 2015 Turkish Society of Cardiology

                This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

                History
                Categories
                Case Report

                Comments

                Comment on this article